Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes
Tier: Core Concepts (CC)

BEFORE YOU BEGIN

These Core Concepts questions build the diagnostic and evaluative framework for hypertension — how blood pressure is accurately measured, how the four BP phenotypes are defined, what the initial workup should include, and how secondary causes are recognized and investigated. Pharmacological reasoning is introduced where it connects directly to the diagnostic findings. Work through each question before reading the rationale. The closing note will orient you to what Tier 1 adds.

1. A nurse records a blood pressure of 164/98 mmHg at an office visit. Review of the technique reveals: the patient sat quietly for 3 minutes before measurement; a standard adult cuff was used on an arm circumference of 37 cm; and coffee was consumed 20 minutes earlier. Which of the following is most likely producing a falsely elevated reading?

A) Coffee consumption within 30 minutes, which causes true sympathetic activation rather than a measurement artifact
B) Using a standard adult cuff on an arm circumference of 37 cm — a cuff bladder that is too small for the arm circumference requires excess external pressure to occlude the brachial artery, transmitting that excess pressure to the manometer and producing a reading falsely elevated above true intra-arterial pressure
C) Measuring after only 3 minutes of seated rest rather than the required 5 minutes
D) Performing the measurement in a clinical setting rather than the patient's home environment
E) Failing to take a second reading 1–2 minutes later and average the two results

ANSWER: B

Rationale:

This question asked you to identify the measurement error most likely to produce a falsely elevated reading. Option B is correct: undersized cuff is one of the most consequential and common sources of BP measurement error. Standard cuff sizing requires that the bladder length cover approximately 80% and the bladder width approximately 40% of the arm circumference. For an arm circumference of 37 cm, a standard adult cuff (bladder typically 12–13 cm wide) is undersized. An undersized cuff requires more external pressure to compress the brachial artery, and this excess pressure is transmitted to the manometer — producing a reading falsely elevated above the true intra-arterial pressure by as much as 5–15 mmHg in some patients.

Option A: Option A is incorrect — caffeine within 30 minutes causes true physiological BP elevation through adenosine receptor blockade and sympathetic activation; this is real BP elevation, not a measurement artifact.
Option C: Option C is incorrect — 3 minutes of rest versus 5 minutes may modestly inflate readings, but the magnitude of cuff size error is larger and more systematic.
Option D: Option D is incorrect — the clinical setting is associated with white coat effect (a real physiological phenomenon, not a mechanical artifact).
Option E: Option E is incorrect — taking a single reading reduces precision but does not systematically produce falsely elevated values.

2. Which of the following correctly states all three diagnostic thresholds for hypertension using ambulatory blood pressure monitoring (ABPM), and explains why these thresholds differ from the office BP threshold of ≥140/90 mmHg?

A) 24-hour mean ≥140/90 mmHg; daytime ≥140/90 mmHg; nighttime ≥130/80 mmHg — the daytime threshold equals office BP because both reflect waking physiological state
B) 24-hour mean ≥130/80 mmHg; daytime mean ≥135/85 mmHg; nighttime mean ≥120/70 mmHg — these thresholds are lower than the office threshold because ABPM averages BP across periods when BP is physiologically lower (particularly during sleep), and because out-of-office readings avoid the white coat effect; a lower threshold is therefore needed to identify the same degree of cardiovascular risk
C) 24-hour mean ≥125/75 mmHg; daytime mean ≥130/80 mmHg; nighttime mean ≥115/65 mmHg — set aggressively lower to account for additional cardiovascular information from 24-hour monitoring
D) 24-hour mean ≥135/85 mmHg; daytime mean ≥140/90 mmHg; nighttime mean ≥125/75 mmHg — the daytime ABPM threshold matches office BP
E) 24-hour mean ≥130/80 mmHg for all time periods — a single threshold applies because cardiovascular risk does not vary by time of day

ANSWER: B

Rationale:

This question asked you to state the correct ABPM thresholds and explain their rationale. Option B is correct: the diagnostic thresholds for hypertension by ABPM are 24-hour mean ≥130/80 mmHg, daytime mean ≥135/85 mmHg, and nighttime mean ≥120/70 mmHg. These thresholds are systematically lower than the office threshold of ≥140/90 mmHg for two reasons: first, ABPM eliminates the white coat effect that inflates office readings; second, the 24-hour mean and nighttime values incorporate the normal physiological BP dip during sleep, producing a mean that is lower than a single daytime office reading. To identify the same degree of cardiovascular risk as an office reading of ≥140/90 mmHg, the ABPM threshold must be set lower.

Option A: Option A is incorrect — the daytime ABPM threshold (≥135/85 mmHg) is lower than the office threshold even for daytime hours, because out-of-office readings eliminate the white coat effect.
Option C: Option C is incorrect — these values are too low and do not correspond to any established guideline standard.
Option D: Option D is incorrect — the 24-hour and daytime values are transposed.
Option E: Option E is incorrect — different thresholds apply for the 24-hour mean, daytime, and nighttime periods, reflecting the physiological variation in normal BP across the circadian cycle.

3. A patient with two office BP readings of 156/98 mmHg undergoes ABPM. Results: 24-hour mean 115/72 mmHg; daytime mean 120/76 mmHg; nighttime mean 113/70 mmHg; nighttime dip 6%. Which of the following most accurately identifies this BP phenotype and its full clinical significance?

A) Sustained hypertension — both office and out-of-office values exceed thresholds; pharmacotherapy is indicated immediately
B) Normotension — all ABPM values are below diagnostic thresholds; no cardiovascular risk
C) Masked hypertension — office BP is normal but out-of-office values are elevated; carries cardiovascular risk equivalent to sustained hypertension
D) White coat hypertension with non-dipping — office BP is elevated but all ABPM values are below diagnostic thresholds; however, this phenotype is not entirely benign, as it carries increased long-term risk of converting to sustained hypertension and modest excess cardiovascular risk compared to true normotension; the nighttime dip of only 6% (below the normal ≥10% threshold) indicates non-dipping status, which independently increases cardiovascular risk — particularly for stroke and LVH (left ventricular hypertrophy) — beyond what the normal daytime values suggest
E) Isolated nocturnal hypertension — the nighttime dip pattern is the only clinically relevant abnormality; white coat effect during office visits is irrelevant to long-term cardiovascular risk

ANSWER: D

Rationale:

This question asked you to fully characterize the BP phenotype and its clinical implications. Option D is correct: this patient has white coat hypertension — elevated office BP (156/98 mmHg) with ABPM values below all diagnostic thresholds (24-hour mean 115/72, daytime 120/76, nighttime 113/70 mmHg — all below ≥130/80, ≥135/85, and ≥120/70 mmHg respectively). White coat hypertension is not equivalent to true normotension: it carries increased long-term risk of converting to sustained hypertension and modest excess cardiovascular risk. Furthermore, the nighttime dip of only 6% is below the normal threshold of ≥10% fall from daytime to nighttime mean. Non-dippers carry higher cardiovascular risk independent of their daytime BP — including increased risk of LVH, stroke, and all-cause cardiovascular mortality.

Option A: Option A is incorrect — ABPM values are all below diagnostic thresholds; this is not sustained hypertension.
Option B: Option B is incorrect — white coat hypertension is not equivalent to true normotension and the non-dipping pattern adds independent cardiovascular risk.
Option C: Option C is incorrect — masked hypertension requires normal office BP with elevated out-of-office readings; this patient has the opposite pattern.
Option E: Option E is incorrect — both the white coat effect and the non-dipping pattern have clinical significance in this patient.

4. Which of the following blood pressure phenotypes is most likely to go completely undetected with office-only BP measurement, and why does it carry particular clinical importance?

A) White coat hypertension — undetected because office BP is falsely elevated; important because of overtreatment risk
B) Sustained hypertension — undetected because patients with consistently elevated BP avoid medical contact; important because it is the most prevalent treatable BP phenotype
C) Non-dipping hypertension — undetected because office measurements occur only during daytime; important because nocturnal BP predicts cardiovascular outcomes independently
D) Masked hypertension — undetected because office BP is normal, triggering no concern and no out-of-office monitoring; clinically important because its prevalence of approximately 10–15% means a substantial proportion of apparently normotensive patients carry a hidden BP burden equivalent in cardiovascular risk to sustained hypertension, including increased risk of LVH, stroke, and coronary artery disease — none of which would be detected or treated without out-of-office measurement
E) Isolated diastolic hypertension — undetected because office systolic readings are normal; important because diastolic hypertension drives cardiovascular risk in middle-aged patients

ANSWER: D

Rationale:

This question asked you to identify the phenotype most likely to be completely missed with office-only measurement and explain its clinical importance. Option D is correct: masked hypertension — normal office BP with elevated out-of-office BP — is by definition invisible to office measurement. The normal office reading generates no clinical concern, so no out-of-office monitoring is ordered. Yet masked hypertension carries cardiovascular risk equivalent to sustained hypertension — including increased rates of LVH, stroke, and coronary artery disease. Its prevalence of approximately 10–15% means a clinically significant proportion of patients who appear normotensive in the office are experiencing ongoing target organ damage.

Option A: Option A is incorrect — white coat hypertension is detected (as an elevated reading) by office measurement; the concern is overdiagnosis, not underdetection.
Option B: Option B is incorrect — sustained hypertension is detected when patients present for evaluation; the issue is healthcare access, not a limitation of office measurement.
Option C: Option C is incorrect — while non-dipping is missed by daytime-only measurement, it is a modifier of risk within an already-diagnosed hypertensive patient rather than a completely hidden independent diagnosis.
Option E: Option E is incorrect — isolated diastolic hypertension is not systematically missed by office measurement; both systolic and diastolic values are routinely recorded.

5. A 52-year-old man with hypertension on lisinopril 20 mg and amlodipine 5 mg presents with worsening BP control after starting ibuprofen 600 mg three times daily for lower back pain. Which of the following best explains how ibuprofen is pharmacologically contributing to his elevated blood pressure?

A) Ibuprofen directly activates the RAAS by stimulating juxtaglomerular renin release through prostaglandin-independent adrenergic pathways
B) Ibuprofen inhibits cyclooxygenase (COX)-mediated renal prostaglandin synthesis, reducing prostaglandin E2 (PGE2) and prostacyclin (PGI2) in the kidney; these prostaglandins normally dilate the renal afferent arteriole and promote natriuresis — their loss causes afferent arteriolar vasoconstriction, sodium and water retention, and direct blunting of the natriuretic effects of diuretics and RAAS inhibitors
C) Ibuprofen reduces lisinopril bioavailability through CYP3A4 induction in intestinal enterocytes, lowering plasma lisinopril levels
D) Ibuprofen reduces hepatic ACE activity through COX-2 inhibition in hepatocytes, paradoxically increasing circulating Ang II
E) Ibuprofen causes direct alpha-1 adrenergic receptor activation in vascular smooth muscle through an off-target effect independent of prostaglandin pathways

ANSWER: B

Rationale:

This question asked you to identify the mechanism of NSAID-induced BP elevation. Option B is correct: ibuprofen inhibits COX enzymes in the kidney — reducing synthesis of PGE2 and prostacyclin (PGI2). These prostaglandins maintain renal afferent arteriolar dilation and promote natriuresis. Their inhibition causes afferent arteriolar vasoconstriction, sodium and water retention, and antagonism of the natriuretic effects of diuretics and RAAS inhibitors. The average BP rise from NSAIDs is 3–5 mmHg, but can be substantially greater in susceptible patients — those with CKD, the elderly, and those on diuretics or RAAS inhibitors. Acetaminophen at standard doses does not meaningfully inhibit renal COX enzymes and is the preferred analgesic substitute.

Option A: Option A is incorrect — ibuprofen does not directly stimulate renin secretion; any secondary RAAS activation is indirect from reduced renal perfusion.
Option C: Option C is incorrect — the interaction is pharmacodynamic (opposing effects on renal sodium handling), not pharmacokinetic.
Option D: Option D is incorrect — ibuprofen does not inhibit hepatic ACE through COX-2; this mechanism is fabricated.
Option E: Option E is incorrect — ibuprofen does not activate alpha-1 adrenergic receptors.

6. Which of the following correctly states the recommended home blood pressure monitoring (HBPM) protocol and the diagnostic threshold for hypertension by this method?

A) Once daily at bedtime for 7 days; all readings included; threshold ≥140/90 mmHg
B) Three readings per morning for 5 days; discard the highest reading each day; average the remainder; threshold ≥130/80 mmHg
C) Twice daily (morning before medications, evening before bed) for at least 7 days; discard day 1 readings; average all remaining readings; threshold ≥135/85 mmHg
D) Twice daily for 3 days at a pharmacy kiosk using a validated automated device; threshold ≥135/85 mmHg
E) Once weekly for one month; five readings per session; discard the first; average the remainder; threshold ≥130/80 mmHg

ANSWER: C

Rationale:

This question asked you to recall the correct HBPM protocol and diagnostic threshold. Option C is correct: the recommended HBPM protocol for diagnostic purposes is twice-daily measurements — morning (before taking antihypertensive medications and before breakfast) and evening (before bed) — for a minimum of 7 days. Day 1 readings are discarded because first-day technique variability and novelty-related physiological changes can produce atypical readings. The remaining readings (days 2–7) are averaged. The diagnostic threshold is ≥135/85 mmHg — lower than the office threshold of ≥140/90 mmHg because out-of-office measurements eliminate the white coat effect.

Option A: Option A is incorrect — once daily at bedtime is not the recommended protocol; both morning and evening readings are required, and the office threshold (≥140/90 mmHg) is not the HBPM threshold.
Option B: Option B is incorrect — discarding the highest reading each day is not part of the protocol; all readings after day 1 are averaged; 3-day duration is insufficient.
Option D: Option D is incorrect — HBPM is patient-performed at home, not at a pharmacy kiosk.
Option E: Option E is incorrect — once weekly over a month is not the standard protocol.

7. A 27-year-old lean man with no family history of hypertension has BP of 174/106 mmHg resistant to two antihypertensives and a serum potassium of 2.7 mEq/L on no diuretics. Which of the following correctly explains why this clinical profile demands secondary evaluation before any further antihypertensive escalation?

A) All patients with Stage 2 hypertension regardless of age or associated features require secondary evaluation before adding a third antihypertensive agent
B) The serum potassium of 2.7 mEq/L may represent dietary insufficiency; correcting potassium alone with supplementation and reassessing BP before any secondary workup is appropriate
C) Resistance to two antihypertensives automatically defines resistant hypertension, which requires catheter-based renal denervation rather than secondary workup
D) Young age of onset without family history or obesity, unexplained hypokalemia without diuretic use, and resistance to two antihypertensive agents together constitute high-yield clinical clues for primary aldosteronism — the most common endocrine cause of hypertension — in which autonomous aldosterone secretion drives potassium wasting, volume expansion, and renin-independent hypertension that will not respond to standard antihypertensives unless the underlying cause is identified; secondary workup starting with an aldosterone-to-renin ratio (ARR) is the correct next step
E) The most appropriate next step is direct adrenal CT imaging to identify an adrenal adenoma before any biochemical screening, because imaging is faster and more specific than the ARR in a young male patient

ANSWER: D

Rationale:

This question asked you to explain why specific clinical features mandate secondary evaluation. Option D is correct: this patient has three convergent high-yield clues for primary aldosteronism. First, age of onset before 30 without family history and lean body habitus argues strongly against primary hypertension. Second, spontaneous hypokalemia without diuretic use (K+ 2.7 mEq/L) is a biochemical hallmark of primary aldosteronism — autonomous aldosterone secretion drives continuous potassium wasting in the collecting duct through ENaC (epithelial sodium channel) upregulation. Third, resistance to two antihypertensives indicates a mechanism that standard drug classes cannot overcome. Primary aldosteronism affects 5–10% of hypertensive patients overall and up to 20% of those with resistant hypertension. The ARR is the first-line screening test.

Option A: Option A is incorrect — Stage 2 hypertension does not universally require secondary evaluation; secondary workup is triggered by specific clinical clues.
Option B: Option B is incorrect — hypokalemia of 2.7 mEq/L in a hypertensive patient without diuretics is a red flag, not a dietary issue.
Option C: Option C is incorrect — catheter-based renal denervation is not a substitute for secondary cause evaluation.
Option E: Option E is incorrect — adrenal CT is a subtype differentiation tool used after biochemical confirmation; it has a ~40% error rate in lateralization and is not the first-line test.

8. A hypertensive patient with unexplained hypokalemia (K+ 3.1 mEq/L, no diuretic use) has an ARR returned as: plasma renin activity 0.3 ng/mL/hr; plasma aldosterone 20 ng/dL; ARR 67. What does this result indicate and what is the appropriate next step?

A) An ARR of 67 with suppressed renin and hypokalemia is diagnostic of primary aldosteronism; spironolactone should be started and adrenal CT ordered simultaneously to plan surgery
B) The suppressed renin is a non-specific finding from any volume-expanded state; the ARR result is uninterpretable and must be repeated after stopping all antihypertensives for 4 weeks
C) An ARR of 67 is below the diagnostic threshold for primary aldosteronism and does not require further workup; the hypokalemia should be managed with dietary potassium
D) The suppressed renin and elevated ARR (well above the suspicious threshold of approximately 20–30) with spontaneous hypokalemia constitutes a strongly positive screening result for primary aldosteronism; however, ARR is a screening test and confirmatory testing is required — standard confirmatory tests are oral sodium loading (24-hour urinary aldosterone >12 mcg/day confirms autonomy) or IV saline infusion test (plasma aldosterone >6 ng/dL after 2 liters of saline over 4 hours confirms autonomy); only after biochemical confirmation does subtype differentiation with adrenal CT and adrenal vein sampling (AVS) proceed
E) Adrenal CT should be performed immediately as the next step to identify the source of aldosterone before any confirmatory biochemical testing

ANSWER: D

Rationale:

This question asked you to interpret a positive ARR and identify the correct next step. Option D is correct: plasma renin activity of 0.3 ng/mL/hr (markedly suppressed), plasma aldosterone of 20 ng/dL, and ARR of 67 — well above the suspicious threshold of approximately 20–30 — in the context of spontaneous hypokalemia is a strongly positive screening result for primary aldosteronism. The pathophysiology is autonomous aldosterone secretion causing volume expansion (which suppresses renin through baroreceptor feedback) while maintaining inappropriately high aldosterone. However, the ARR is a screening test with imperfect specificity — false positives occur with beta-blocker use (which suppresses renin), dehydration, and renal impairment. Confirmatory testing is mandatory before treatment decisions.

Option A: Option A is incorrect — ARR alone is not diagnostic; confirmatory testing is required.
Option B: Option B is incorrect — this result (ARR 67, suppressed renin, hypokalemia) is not ambiguous and does not require repeat before proceeding.
Option C: Option C is incorrect — an ARR of 67 is well above the suspicious threshold.
Option E: Option E is incorrect — adrenal CT is used for subtype differentiation after biochemical confirmation, not as the immediate next step after a positive screening ARR.

9. A 36-year-old woman with resistant hypertension has renal CT angiography showing a mid-renal artery "string of beads" appearance on the right side with elevated plasma renin activity. Which of the following most accurately characterizes this finding and its treatment implications?

A) This is ostial atherosclerotic renal artery stenosis; optimal medical therapy is preferred based on the ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) and CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trials
B) This is renal artery thromboembolism; immediate anticoagulation and thrombolysis are required before antihypertensive therapy
C) This is fibromuscular dysplasia (FMD) — a non-atherosclerotic, non-inflammatory condition affecting predominantly young to middle-aged women; the mid-renal artery "string of beads" appearance is pathognomonic; unlike atherosclerotic stenosis (where trials showed no benefit of stenting over medical therapy), FMD-related stenosis responds well to percutaneous transluminal angioplasty without stenting, which frequently achieves cure or marked BP improvement; the elevated plasma renin activity confirms hemodynamically significant RAAS activation from reduced renal perfusion distal to the lesion
D) This is renal cell carcinoma with vascular invasion causing a pseudostenosis artifact; surgical resection is required before antihypertensive therapy can be optimized
E) This is an incidental finding unrelated to her resistant hypertension; intensification of pharmacotherapy with a third agent is the appropriate next step

ANSWER: C

Rationale:

This question asked you to identify the FMD finding and its specific treatment implication. Option C is correct: the "string of beads" appearance on renal CT angiography in a young woman is pathognomonic of fibromuscular dysplasia — a non-atherosclerotic, non-inflammatory dysplasia of the arterial media that predominantly affects young to middle-aged women. The mid and distal renal artery location further distinguishes FMD from atherosclerotic disease, which characteristically produces ostial stenosis in older patients with multiple cardiovascular risk factors. The elevated plasma renin activity confirms hemodynamically significant stenosis — reduced perfusion pressure distal to the lesion chronically activates juxtaglomerular renin secretion, driving renin-dependent hypertension. Crucially, unlike atherosclerotic renal artery stenosis (where the ASTRAL and CORAL trials demonstrated no benefit of endovascular stenting over optimal medical therapy), FMD responds very well to percutaneous transluminal angioplasty without stenting, which is frequently curative in young patients.

Option A: Option A is incorrect — the mid-arterial "string of beads" pattern identifies FMD, not atherosclerotic disease.
Option B: Option B is incorrect — renal artery thromboembolism presents with acute flank pain and hematuria in a different clinical context.
Option D: Option D is incorrect — renal cell carcinoma does not produce this angiographic finding.
Option E: Option E is incorrect — FMD is not an incidental finding; it is the mechanistic cause of this patient's resistant hypertension.

10. A patient with hypertension on metoprolol 50 mg daily, hydrochlorothiazide 25 mg daily, and amlodipine 10 mg daily undergoes ARR screening. Which of the following correctly describes the directional effects of metoprolol and hydrochlorothiazide on the ARR result?

A) Metoprolol raises aldosterone and lowers renin simultaneously — always producing a false-positive ARR requiring drug discontinuation before any valid result can be obtained
B) Hydrochlorothiazide suppresses renin by causing volume expansion; metoprolol stimulates renin by reducing cardiac output — both lower the ARR and produce false-negative results
C) Neither drug significantly affects the ARR; only aldosterone antagonists (spironolactone, eplerenone) require medication adjustment before ARR testing
D) Metoprolol suppresses renin secretion by blocking beta-1 adrenergic stimulation of juxtaglomerular cells — this raises the ARR (lower denominator) and can produce false-positive results; hydrochlorothiazide stimulates renin secretion through volume depletion and reduced macula densa sodium delivery — this lowers the ARR (higher denominator) and can produce false-negative results; the two drugs push the ARR in opposite directions and their effects must be considered when interpreting results
E) Both drugs suppress the ARR by reducing aldosterone secretion — metoprolol through adrenal beta-receptor blockade and hydrochlorothiazide through volume-dependent aldosterone suppression

ANSWER: D

Rationale:

This question asked you to identify the directional effects of specific medications on the ARR. Option D is correct: the ARR is the ratio of plasma aldosterone to plasma renin activity, so any drug affecting renin changes the ratio even without changing aldosterone. Metoprolol suppresses renin secretion by blocking beta-1 adrenergic stimulation of juxtaglomerular cells — reducing the denominator of the ARR and raising the ratio, potentially producing a false-positive result. Hydrochlorothiazide stimulates renin secretion through volume depletion and reduced sodium delivery to the macula densa — increasing the denominator and lowering the ratio, potentially masking true primary aldosteronism (false-negative). Amlodipine has negligible effects and is a preferred antihypertensive to continue during ARR screening.

Option A: Option A is incorrect — beta-blockers suppress renin (not raise aldosterone), and the effect is not always definitively false-positive.
Option B: Option B is incorrect — the directions are exactly reversed; hydrochlorothiazide stimulates renin and metoprolol suppresses it.
Option C: Option C is incorrect — both drugs significantly affect the ARR.
Option E: Option E is incorrect — neither drug primarily suppresses aldosterone; their effects are on renin.

11. Which of the following correctly identifies the components of the recommended baseline laboratory and diagnostic workup for all newly diagnosed hypertensive patients?

A) Plasma metanephrines, 24-hour urine aldosterone, renal artery duplex ultrasound, and overnight dexamethasone suppression test — required to exclude the four most common secondary causes before any antihypertensive is prescribed
B) Serum creatinine, eGFR, urinalysis with microscopy, basic metabolic panel (electrolytes, glucose), lipid panel, ECG, and TSH — thyroid-stimulating hormone — (to identify renal impairment and CKD staging, electrolyte abnormalities suggesting secondary causes, atherosclerotic cardiovascular disease (ASCVD) risk factors for risk calculation, target organ damage including LVH by voltage criteria, and contributory thyroid dysfunction)
C) Echocardiography, renal ultrasound, and ABPM — mandatory imaging and confirmation studies required in all patients before initiating any antihypertensive therapy
D) Complete blood count, liver function tests, coagulation panel, and BNP (B-type natriuretic peptide) — required to assess end-organ damage and confirm drug safety
E) Fasting insulin, plasma aldosterone, and urine cortisol — required in all newly diagnosed patients because metabolic causes are present in the majority of cases

ANSWER: B

Rationale:

This question asked you to identify the standard baseline workup for newly diagnosed hypertension. Option B is correct: the recommended baseline workup includes serum creatinine and eGFR (to stage CKD and determine drug appropriateness), urinalysis with microscopy (proteinuria suggests hypertensive nephrosclerosis or primary renal disease; hematuria raises concern for glomerulonephritis or renovascular disease; casts indicate intrinsic renal disease), basic metabolic panel including electrolytes and fasting glucose (hypokalemia without diuretics is a biochemical red flag for primary aldosteronism; glucose identifies diabetes, which changes treatment targets), lipid panel (LDL, HDL, total cholesterol, and triglycerides for the Pooled Cohort Equations ASCVD risk calculation), ECG (LVH by Sokolow-Lyon or Cornell voltage criteria, atrial fibrillation, prior MI by Q waves), and TSH (both hypothyroidism and hyperthyroidism cause hypertension through distinct mechanisms — each is treatable with BP normalization on correction).

Option A: Option A is incorrect — plasma metanephrines, 24-hour urine aldosterone, renal artery imaging, and dexamethasone suppression tests are secondary cause tests ordered based on specific clinical suspicion, not universal baseline screening.
Option C: Option C is incorrect — echocardiography and renal ultrasound are additional investigations when specifically indicated.
Option D: Option D is incorrect — liver function tests, coagulation panels, and BNP are not part of the standard baseline hypertension workup.
Option E: Option E is incorrect — these are not universal baseline tests.

12. A patient with a confirmed pheochromocytoma is scheduled for elective adrenalectomy. The surgical team wants to give IV propranolol for intraoperative heart rate control before establishing alpha-blockade. The anesthesiologist declines and explains the specific pharmacological danger. Which of the following best explains the physiological basis for the alpha-before-beta rule?

A) Beta-blockers given before adequate alpha-blockade remove beta-2-mediated peripheral vasodilation — which was partially counteracting the alpha-1-mediated vasoconstriction from tumor catecholamines — leaving alpha-1 vasoconstriction completely unopposed; catecholamine surges during intraoperative tumor manipulation then produce an unimpeded hypertensive crisis that can be catastrophic
B) Beta-blockers inhibit hepatic catecholamine degradation through MAO (monoamine oxidase) blockade, raising plasma norepinephrine and epinephrine to dangerous levels during tumor manipulation
C) Beta-blockers directly stimulate catecholamine secretion from pheochromocytoma cells by activating adenylyl cyclase within the tumor, triggering a paradoxical norepinephrine surge
D) Beta-blockers cause acute mineralocorticoid receptor (MR) activation in the adrenal cortex, producing aldosterone-mediated volume expansion that synergizes with catecholamine-driven vasoconstriction
E) Beta-blockers reduce coronary blood flow so dramatically in the presence of pheochromocytoma-driven tachycardia that intraoperative myocardial ischemia becomes irreversible before surgical correction can be attempted

ANSWER: A

Rationale:

This question asked you to explain the pharmacological basis of the alpha-before-beta rule. Option A is correct: pheochromocytomas secrete catecholamines — norepinephrine and/or epinephrine — that act on both alpha-1 adrenergic receptors (producing vasoconstriction) and beta-2 adrenergic receptors (producing some peripheral vasodilation that partially counteracts the alpha-1 effect). When a beta-blocker is given without prior alpha-blockade, beta-2 mediated vasodilation is abolished while alpha-1 vasoconstriction from tumor catecholamines remains fully active and unopposed. During intraoperative tumor handling, large catecholamine surges hit completely unblocked alpha-1 receptors — producing extreme, potentially lethal hypertensive crisis. The correct preoperative sequence is: alpha-blockade first (phenoxybenzamine — a non-selective irreversible alpha-blocker — or doxazosin — a selective reversible alpha-1 blocker) for 10–14 days preoperatively, then beta-blockade for rate control 2–3 days before surgery, only after adequate alpha-blockade is established.

Option B: Option B is incorrect — catecholamine degradation is mediated by MAO and COMT (catechol-O-methyltransferase), not by beta-receptor-mediated hepatic pathways; beta-blockers do not inhibit either enzyme.
Option C: Option C is incorrect — beta-blockers do not directly stimulate catecholamine release from pheochromocytoma cells through adenylyl cyclase activation; tumor secretion is triggered by physical pressure and specific pharmacological stimuli (opioids, metoclopramide, glucagon, tyramine), not by beta-receptor stimulation.
Option D: Option D is incorrect — beta-blockers do not activate mineralocorticoid receptors or stimulate aldosterone secretion.
Option E: Option E is incorrect — the primary documented hazard is the hypertensive crisis from unopposed alpha-1 vasoconstriction, not myocardial ischemia.

13. A patient with a known pheochromocytoma presents in hypertensive crisis after cocaine use. Which antihypertensive is most dangerous in this scenario and why?

A) IV phentolamine — dangerous because non-selective alpha-blockade in catecholamine excess causes uncontrollable reflex tachycardia that worsens cardiac workload
B) IV nicardipine — dangerous because rapid BP reduction with an IV CCB (calcium channel blocker) in pheochromocytoma precipitates tumor rupture through excessive vasoactive changes
C) IV sodium nitroprusside — dangerous because direct arterial vasodilation triggers a renin surge that overwhelms the antihypertensive effect and worsens the crisis
D) IV labetalol — dangerous because combined alpha and beta blockade in this setting lowers BP too rapidly, causing cerebral hypoperfusion
E) Non-selective beta-blockers such as propranolol given without prior alpha-blockade — in this scenario, cocaine and the pheochromocytoma together create massive catecholamine excess driving alpha-1-mediated vasoconstriction; propranolol blocks beta-2-mediated vasodilation while leaving alpha-1 vasoconstriction completely unopposed, worsening the crisis; cocaine-associated hypertensive emergencies specifically contraindicate beta-blockers without prior alpha-blockade; preferred management is benzodiazepines and IV phentolamine for refractory BP elevation

ANSWER: E

Rationale:

This question asked you to identify the most dangerous antihypertensive in a dual-catecholamine-excess scenario. Option E is correct: this patient simultaneously has autonomous catecholamine secretion from the pheochromocytoma and pharmacologically amplified catecholamine effect from cocaine — which blocks neuronal norepinephrine reuptake, massively increasing synaptic norepinephrine concentrations. Both conditions drive hypertension primarily through alpha-1-mediated vasoconstriction. Non-selective beta-blockers are contraindicated because they block beta-2-mediated vasodilation while leaving alpha-1 vasoconstriction fully unopposed — worsening vasoconstriction and hypertension. This principle applies to cocaine-associated hypertensive emergencies even without a concurrent pheochromocytoma. The recommended management is benzodiazepines (which reduce central sympathetic activation) and IV phentolamine (non-selective alpha-blocker) for refractory hypertension.

Option A: Option A is incorrect — IV phentolamine is actually the preferred treatment in this scenario, not the dangerous one.
Option B: Option B is incorrect — IV CCBs do not cause tumor rupture; this mechanism is fabricated.
Option C: Option C is incorrect — sodium nitroprusside is an acceptable agent for hypertensive emergencies including those from catecholamine excess.
Option D: Option D is incorrect — while labetalol's use in cocaine-associated hypertension is debated, the clearly most dangerous agent is a pure non-selective beta-blocker without prior alpha-blockade.

14. A 1 mg overnight dexamethasone suppression test (DST) returns a morning cortisol of 3.6 mcg/dL (positive; normal suppression is <1.8 mcg/dL) in a hypertensive patient being evaluated for Cushing syndrome. Which of the following most accurately describes what this result indicates and the correct next step?

A) A positive DST is diagnostic of Cushing syndrome; transsphenoidal surgery referral is appropriate without further testing
B) A positive DST indicates primary adrenal insufficiency — the adrenal gland fails to suppress cortisol in response to dexamethasone because cortisol reserves are exhausted
C) This result confirms ectopic ACTH secretion; immediate CT of the chest is the correct next step before any further biochemical testing
D) A positive DST indicates failure of normal HPA axis suppression by exogenous glucocorticoid — this occurs when cortisol production is autonomous rather than feedback-sensitive; it is a sensitive screening result requiring confirmation with a second-line test (24-hour urinary free cortisol or late-night salivary cortisol) before a definitive diagnosis of Cushing syndrome is made; false positives occur with obesity, depression, alcoholism, and medications that accelerate dexamethasone metabolism such as phenytoin, rifampicin, and carbamazepine
E) A 1 mg overnight DST is not a validated screening tool; a 2 mg test or CRH (corticotropin-releasing hormone) stimulation test must be performed first in all patients before any cortisol suppression interpretation is made

ANSWER: D

Rationale:

This question asked you to interpret a positive overnight DST and identify the next diagnostic step. Option D is correct: the 1 mg overnight DST exploits normal HPA axis physiology — in non-Cushing individuals, exogenous dexamethasone suppresses CRH and ACTH through negative feedback, producing a low morning cortisol (< 1.8 mcg/dL). When cortisol production is autonomous — as in Cushing syndrome from any cause — this feedback suppression does not occur and cortisol remains elevated. The test is highly sensitive (~95–98%) but not specific — false positives occur with physiological hypercortisolism states (obesity, major depression, alcoholism) and with medications that accelerate dexamethasone clearance through CYP3A4 induction (phenytoin, rifampicin, carbamazepine). Because of this imperfect specificity, a positive result must be confirmed with a second independent biochemical test (24-hour urinary free cortisol or late-night salivary cortisol) before a diagnosis is established. Only after biochemical confirmation does anatomical localization proceed.

Option A: Option A is incorrect — the DST is a screening test, not diagnostic; the etiology requires further characterization before surgical referral.
Option B: Option B is incorrect — adrenal insufficiency produces low cortisol at all times; the DST is not used to diagnose it.
Option C: Option C is incorrect — the DST result does not identify the etiology of Cushing syndrome; it only confirms autonomous cortisol production.
Option E: Option E is incorrect — the 1 mg overnight DST is the established standard first-line screening tool endorsed by Endocrine Society guidelines.

15. A kidney transplant recipient on tacrolimus develops worsening hypertension from 128/80 mmHg to 158/98 mmHg over 4 months. Which of the following correctly identifies the mechanism of calcineurin inhibitor-induced hypertension and identifies both the preferred antihypertensive and the agent that must be specifically avoided?

A) Calcineurin inhibitors cause direct aldosterone receptor agonism in the kidney; spironolactone is preferred and non-dihydropyridine CCBs must be avoided
B) Calcineurin inhibitors cause beta-1 adrenergic receptor stimulation raising cardiac output; beta-blockers are preferred and thiazides must be avoided
C) Calcineurin inhibitors cause renal afferent arteriolar vasoconstriction, SNS (sympathetic nervous system) activation, endothelin-1 upregulation, and sodium retention; dihydropyridine CCBs — particularly amlodipine — are preferred because they dilate the afferent arteriole, lowering BP and partially mitigating calcineurin inhibitor-induced nephrotoxicity; diltiazem and verapamil must be avoided because they inhibit CYP3A4, substantially increasing calcineurin inhibitor blood levels and the risk of nephrotoxicity and systemic toxicity
D) Calcineurin inhibitors cause hypertension solely through endothelial nitric oxide (NO) synthase inhibition; ACE inhibitors are preferred; thiazides must be avoided
E) Calcineurin inhibitors cause hypertension through enhanced renal prostaglandin synthesis driving afferent arteriole dilation paradoxically increasing glomerular pressure; COX inhibitors are preferred and CCBs must be avoided

ANSWER: C

Rationale:

This question asked you to identify the mechanism of calcineurin inhibitor-induced hypertension, the preferred antihypertensive, and the agent requiring avoidance. Option C is correct on all three counts: calcineurin inhibitors cause hypertension primarily through renal afferent arteriolar vasoconstriction — reducing renal blood flow and activating the RAAS — along with direct SNS activation, endothelin-1 upregulation, and sodium retention. Dihydropyridine CCBs, particularly amlodipine, are preferred because they lower BP through afferent arteriolar vasodilation and have minimal CYP3A4 inhibitory activity. Diltiazem and verapamil are potent CYP3A4 inhibitors — co-administration substantially increases calcineurin inhibitor plasma concentrations, raising the risk of nephrotoxicity, neurotoxicity, and other adverse effects. This drug interaction is clinically significant and potentially organ-threatening.

Option A: Option A is incorrect — calcineurin inhibitors do not cause aldosterone receptor agonism.
Option B: Option B is incorrect — calcineurin inhibitors do not stimulate cardiac beta-1 receptors.
Option D: Option D is incorrect — while calcineurin inhibitors do impair endothelial NO production, ACE inhibitors are not the specifically preferred first agent; the CYP3A4 interaction is the critical safety issue.
Option E: Option E is incorrect — calcineurin inhibitors do not stimulate prostaglandin synthesis; this mechanism is fabricated.

16. Which of the following correctly summarizes when antihypertensive pharmacotherapy should be initiated, based on the 2017 ACC/AHA risk-stratified framework?

A) Pharmacotherapy is recommended for all patients with any BP above 120/80 mmHg because every mmHg reduction provides proportional cardiovascular benefit regardless of baseline risk
B) Pharmacotherapy is indicated only when BP exceeds 160/100 mmHg regardless of cardiovascular risk, comorbidities, or target organ damage
C) For Stage 1 hypertension (systolic 130–139 mmHg or diastolic 80–89 mmHg), pharmacotherapy is initiated when 10-year ASCVD risk is ≥10%, or when established cardiovascular disease, CKD, or diabetes mellitus is present; lifestyle modification with reassessment in 3–6 months is appropriate when none of these criteria are met; for Stage 2 hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg), pharmacotherapy is recommended for all patients, often with combination therapy from the outset when BP is ≥160/100 mmHg
D) Pharmacotherapy is never appropriate at Stage 1 hypertension — it is a lifestyle intervention category only regardless of comorbidities or ASCVD risk
E) The treatment initiation decision is based solely on 10-year ASCVD risk; BP stage does not independently determine when pharmacotherapy begins

ANSWER: C

Rationale:

This question asked you to state the correct 2017 ACC/AHA treatment initiation framework. Option C is correct: the guidelines establish a two-tier approach based on BP stage and cardiovascular risk. At Stage 1 hypertension (systolic 130–139 mmHg or diastolic 80–89 mmHg), pharmacotherapy is initiated when 10-year ASCVD risk ≥10%, established cardiovascular disease, CKD, or diabetes mellitus is present — patients with the greatest absolute benefit from BP reduction. When none of these criteria are present, lifestyle modification with structured follow-up is appropriate. At Stage 2 hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg), pharmacotherapy is recommended for all patients regardless of ASCVD risk, typically with combination therapy when BP is ≥160/100 mmHg.

Option A: Option A is incorrect — pharmacotherapy is not recommended for all patients with BP above 120/80 mmHg; elevated BP (120–129/<80 mmHg) is managed with lifestyle modification.
Option B: Option B is incorrect — Stage 2 (≥140/90 mmHg) warrants pharmacotherapy in all patients, not only when BP exceeds 160/100 mmHg.
Option D: Option D is incorrect — Stage 1 does warrant pharmacotherapy when high-risk features are present.
Option E: Option E is incorrect — BP stage itself drives Stage 2 treatment decisions regardless of calculated ASCVD risk.

17. At an initial hypertensive evaluation, bilateral arm BP measurements show 176/100 mmHg in the right arm and 150/84 mmHg in the left arm — a difference of 26 mmHg systolic. Which of the following correctly identifies the clinical significance of this finding and the appropriate response?

A) An inter-arm difference greater than 15 mmHg is within normal biological variation; the average of both arm readings should be used for subsequent BP decisions
B) This finding is immediately diagnostic of aortic dissection; CT angiography must be performed before any antihypertensive is prescribed
C) This finding may indicate subclavian artery stenosis or aortic coarctation causing unequal arterial perfusion; a difference greater than 15 mmHg between arms warrants vascular evaluation; the higher reading arm (right arm, 176/100 mmHg) should be used for all subsequent measurements and management decisions — using the lower arm reading would underestimate the true systemic BP and lead to chronic undertreatment
D) The lower left arm reading should be used for subsequent BP monitoring because it reflects the more accurate cardiac output and is less influenced by peripheral vascular resistance
E) Both arm readings must be remeasured simultaneously using two separate devices before any clinical decision, as a single bilateral measurement is insufficient to confirm an inter-arm difference

ANSWER: C

Rationale:

This question asked you to interpret a significant inter-arm BP difference and identify the correct clinical response. Option C is correct: an inter-arm BP difference of more than 15 mmHg is clinically significant and warrants vascular evaluation. Normal inter-arm differences are generally less than 10 mmHg; a difference of 26 mmHg is substantially outside this range. The differential diagnosis includes subclavian artery stenosis (which reduces perfusion pressure distal to the stenosis in one arm, lowering cuff-measured BP on that side) and aortic coarctation (a congenital narrowing of the aorta that produces higher BP proximal to the stenosis). The management protocol has two components: first, evaluate the vascular cause with appropriate imaging; second, use the higher reading arm (right arm, 176/100 mmHg) for all future BP measurements, because the lower left arm reading is artificially reduced by reduced perfusion pressure — using it would systematically underestimate the true systemic BP and result in undertreatment.

Option A: Option A is incorrect — a 26 mmHg inter-arm difference is not within normal variation; it is a clinically significant finding requiring evaluation.
Option B: Option B is incorrect — while aortic dissection can produce inter-arm BP differences, it is not the only cause and requires additional features (severe tearing pain, hemodynamic instability, widened mediastinum) to be the leading diagnosis; CT angiography is not the immediate first step based on this finding alone in a stable patient.
Option D: Option D is incorrect — the lower arm reading reflects reduced perfusion pressure from arterial disease, not higher accuracy.
Option E: Option E is incorrect — a 26 mmHg difference on careful initial bilateral measurement is already clinically significant and warrants action.

18. A 57-year-old man with hypertension, LVH on ECG, and microalbuminuria (urine ACR — albumin-to-creatinine ratio — 88 mg/g) requires antihypertensive therapy. Which drug class most specifically addresses both LVH and microalbuminuria through mechanisms beyond BP reduction alone?

A) Dihydropyridine CCBs — preferred because they reduce LVH through direct inhibition of voltage-gated calcium channels in cardiomyocytes and reduce albuminuria through afferent vasodilation lowering filtration pressure
B) Thiazide diuretics — preferred because volume reduction through natriuresis addresses the common upstream mechanism of both LVH and hyperfiltration
C) Beta-blockers — preferred because LVH indicates sympathetic overactivation; beta-1 blockade directly reverses adrenergic hypertrophic remodeling and simultaneously reduces albuminuria by suppressing renin
D) Mineralocorticoid receptor antagonists (MRAs) — preferred because aldosterone-mediated fibrosis is the dominant mechanism of both LVH and glomerulosclerosis; MRA therapy most directly reverses this pathophysiology
E) ACE inhibitors or ARBs — preferred because RAAS blockade attenuates Ang II-mediated cardiomyocyte hypertrophy and myocardial fibrosis through AT1 (angiotensin type 1) receptor inhibition of MAP kinase and TGF-β (transforming growth factor-beta) signaling, and reduces albuminuria through preferential efferent arteriole vasodilation lowering intraglomerular hydraulic pressure — providing target organ protection at both the cardiac and renal level that exceeds what BP reduction alone achieves

ANSWER: E

Rationale:

This question asked you to identify the drug class most specifically indicated by the combination of LVH and microalbuminuria. Option E is correct: RAAS inhibitors — ACE inhibitors and ARBs — are the preferred class when hypertension coexists with LVH and microalbuminuria because they address both target organ abnormalities through mechanisms independent of BP lowering. For LVH: Ang II drives cardiomyocyte hypertrophy and myocardial fibrosis through AT1 receptor-mediated activation of growth-signaling cascades including MAP kinase, TGF-β, and NF-κB (nuclear factor kappa-B). ACE inhibitor or ARB therapy blocks these pro-fibrotic and pro-hypertrophic signals. The LIFE trial (comparing losartan to atenolol at equivalent BP reduction) demonstrated superior LVH regression and stroke reduction with losartan, confirming cardiac protection beyond BP lowering alone. For microalbuminuria: RAAS inhibitors preferentially vasodilate the efferent arteriole, reducing intraglomerular hydraulic pressure and slowing the progression of hypertensive and diabetic nephropathy.

Option A: Option A is incorrect — CCBs produce modest LVH regression but do not reduce albuminuria through an established glomerular protection mechanism comparable to RAAS blockade.
Option B: Option B is incorrect — thiazides address volume but do not specifically target the pro-fibrotic and intraglomerular pressure mechanisms.
Option C: Option C is incorrect — beta-blockers produce less LVH regression than RAAS inhibitors in comparative trials and do not reduce albuminuria through the efferent vasodilation mechanism.
Option D: Option D is incorrect — while MRAs are useful add-on therapy, the primary evidence base for LVH regression and microalbuminuria reduction belongs to RAAS inhibitors.

19. A 53-year-old man with hypertension and OSA (obstructive sleep apnea) on CPAP (continuous positive airway pressure) therapy remains uncontrolled on three antihypertensive agents. Which of the following most accurately explains the pathophysiology of OSA-driven resistant hypertension and identifies the most specifically targeted pharmacological addition?

A) OSA causes hypertension only through mechanical means — elevated intrathoracic pressure compresses the pulmonary vasculature; loop diuretics are the most pharmacologically targeted addition
B) OSA causes hypertension exclusively through sustained nocturnal hypoxia causing endothelial nitric oxide (NO) depletion; ACE inhibitors are the most specifically targeted addition
C) OSA causes hypertension through repetitive nocturnal hypoxemia triggering SNS (sympathetic nervous system) surges that persist into daytime, RAAS upregulation driven by SNS-mediated renin release, direct hypoxia-driven aldosterone secretion through HIF (hypoxia-inducible factor) pathways, and endothelial dysfunction from oxidative stress; together these create a multi-mechanism neurohormonal environment that resists agents targeting only one pathway; mineralocorticoid receptor antagonists are particularly effective fourth-line additions in OSA-associated resistant hypertension because they directly address the concurrent aldosterone excess that CPAP therapy incompletely corrects
D) OSA-associated hypertension responds only to CPAP — pharmacological therapy is ineffective because BP remits when sleep apnea is adequately treated; optimize CPAP adherence before adjusting antihypertensives
E) OSA causes hypertension through renin secretion from hypoxic juxtaglomerular cell activation; beta-blockers that suppress renin are the most specifically targeted first-line addition

ANSWER: C

Rationale:

This question asked you to identify OSA's multi-mechanism contribution to resistant hypertension and the most targeted pharmacological addition. Option C is correct: OSA drives resistant hypertension through multiple interacting neurohormonal pathways. Repetitive nocturnal hypoxemia and hypercapnia during apneic episodes trigger sympathetic surges that sensitize brainstem sympathoexcitatory centers, producing persistent daytime SNS hyperactivation. This SNS activation drives renin secretion, upregulating the RAAS. Simultaneously, intermittent hypoxia directly stimulates aldosterone secretion from the adrenal cortex through HIF pathways, independently of Ang II. CPAP interrupts the nocturnal hypoxemic trigger but produces only a modest average BP reduction (approximately 2–3 mmHg) — insufficient as sole intervention when hypertension is resistant to three agents. Mineralocorticoid receptor antagonists are specifically effective in OSA-associated resistant hypertension because they directly address the aldosterone excess that CPAP does not fully correct.

Option A: Option A is incorrect — the systemic hypertension from OSA is neurohormonal, not primarily from pulmonary vascular backloading.
Option B: Option B is incorrect — OSA's dominant mechanism is SNS/RAAS/aldosterone activation, not endothelial NO depletion alone.
Option D: Option D is incorrect — pharmacological therapy is necessary even with CPAP.
Option E: Option E is incorrect — while renin release is part of OSA's effects, beta-blockers are not the first-line add-on; MRAs have stronger targeted evidence.

20. A patient on amlodipine and lisinopril for hypertension is started on venlafaxine (an SNRI — serotonin-norepinephrine reuptake inhibitor) for depression. His BP rises from 124/76 mmHg to 148/94 mmHg within 3 weeks. Which of the following best explains the pharmacological mechanism of venlafaxine-induced BP elevation?

A) Venlafaxine inhibits MAO (monoamine oxidase), preventing norepinephrine degradation at adrenergic synapses — the same mechanism as MAOI antidepressants
B) Venlafaxine blocks serotonin 5-HT2A (type 2A serotonin) receptors in vascular smooth muscle, causing direct vasoconstriction through a receptor pathway independent of catecholamine signaling
C) Venlafaxine activates the RAAS through serotonin-mediated hepatic angiotensinogen upregulation, producing aldosterone-driven volume expansion
D) Venlafaxine inhibits neuronal norepinephrine reuptake at central and peripheral sympathetic synapses, increasing synaptic norepinephrine concentration; at moderate to higher doses this noradrenergic effect activates alpha-1 receptors in resistance arterioles, raising systemic vascular resistance and BP in a dose-dependent manner — requiring BP monitoring when initiating or dose-escalating venlafaxine or duloxetine
E) Venlafaxine blocks the renal organic cation transporter (OCT), reducing tubular secretion of lisinopril and raising its plasma levels paradoxically — causing reflex hypertension from excessive initial BP reduction followed by baroreceptor-mediated rebound

ANSWER: D

Rationale:

This question asked you to identify the mechanism of venlafaxine-induced BP elevation. Option D is correct: venlafaxine inhibits both the serotonin transporter (SERT) and the norepinephrine transporter (NET). At low doses, serotonin reuptake inhibition predominates. At moderate to higher doses, NET inhibition becomes clinically significant — blocking neuronal norepinephrine reuptake at central and peripheral sympathetic synapses increases synaptic norepinephrine concentration. In the periphery, elevated norepinephrine activates alpha-1 adrenergic receptors in resistance arterioles, raising systemic vascular resistance and BP. This is a dose-dependent mechanism and is one of the most commonly missed drug-induced causes of hypertension in clinical practice. BP monitoring after initiating or dose-escalating SNRIs is explicitly recommended.

Option A: Option A is incorrect — venlafaxine is not an MAO inhibitor; it blocks the norepinephrine transporter (NET), not monoamine oxidase.
Option B: Option B is incorrect — venlafaxine does not block 5-HT2A receptors; it inhibits serotonin reuptake at SERT.
Option C: Option C is incorrect — venlafaxine does not upregulate hepatic angiotensinogen through serotonin pathways; this mechanism is fabricated.
Option E: Option E is incorrect — venlafaxine does not clinically significantly inhibit the renal OCT or affect lisinopril pharmacokinetics in the manner described.

21. A patient on bevacizumab (a VEGF — vascular endothelial growth factor — inhibitor) for colorectal cancer develops hypertension with BP rising from 120/72 mmHg to 162/102 mmHg after 4 weeks. Which of the following best explains the mechanism of VEGF inhibitor-induced hypertension?

A) Bevacizumab activates the RAAS by directly stimulating juxtaglomerular renin secretion through VEGF receptor blockade
B) Bevacizumab causes direct alpha-1 adrenergic receptor activation in vascular smooth muscle — VEGF physiologically inhibits alpha-1 receptors and its blockade unmasks vasoconstriction
C) Bevacizumab reduces endothelial NO (nitric oxide) production by blocking VEGF-stimulated activation of eNOS (endothelial NO synthase); reduced NO bioavailability impairs vascular smooth muscle relaxation, increases systemic vascular resistance, and elevates BP — explaining the high prevalence of hypertension (up to 30%) seen with VEGF inhibitor therapy
D) Bevacizumab directly inhibits the COX (cyclooxygenase) prostaglandin synthesis pathway in endothelial cells, reducing renal afferent arteriolar vasodilation and promoting sodium retention — an identical mechanism to NSAIDs
E) Bevacizumab reduces renal tubular sodium excretion by blocking VEGF-mediated aquaporin channel expression in the collecting duct, producing volume-dependent hypertension responsive only to diuretics

ANSWER: C

Rationale:

This question asked you to identify the mechanism of VEGF inhibitor-induced hypertension. Option C is correct: VEGF is a physiological signal for endothelial NO production — it activates eNOS in endothelial cells through VEGFR2 (VEGF receptor 2) signaling, stimulating continuous NO synthesis that maintains vasodilation, low systemic vascular resistance, and normal BP. When bevacizumab or other anti-VEGF agents block this signaling pathway, eNOS activation is impaired and NO bioavailability falls. The resulting increase in vascular tone raises systemic vascular resistance and BP, accounting for the high prevalence (up to 30%) of hypertension with VEGF inhibitors. Standard antihypertensives — CCBs and RAAS inhibitors most commonly — are used to manage the induced hypertension.

Option A: Option A is incorrect — bevacizumab does not directly stimulate juxtaglomerular renin secretion; its mechanism is endothelial NO depletion from VEGFR2 blockade.
Option B: Option B is incorrect — VEGF does not physiologically inhibit alpha-1 adrenergic receptors; its vasoprotective effect is through NO production; this mechanism is fabricated.
Option D: Option D is incorrect — bevacizumab is a monoclonal antibody targeting circulating VEGF protein; it does not inhibit COX enzymes or prostaglandin synthesis.
Option E: Option E is incorrect — bevacizumab does not affect aquaporin channel expression in the renal collecting duct; this mechanism is fabricated.

22. A 64-year-old man with hypertension develops sudden severe tearing chest pain radiating to his back, and a CXR (chest X-ray) shows a widened mediastinum. His bilateral arm BPs are 178/108 mmHg and 176/106 mmHg. Which antihypertensive approach is most appropriate for immediate BP management?

A) Oral amlodipine 10 mg and lisinopril 10 mg simultaneously — this oral combination is appropriate for urgent BP reduction and can be initiated in the emergency department
B) IV labetalol or IV esmolol first to reduce heart rate and cardiac rate of pressure rise (dP/dt), minimizing aortic wall shear stress — then add a vasodilator such as IV nicardipine or sodium nitroprusside if systolic BP remains above target after heart rate is controlled; target systolic BP <120 mmHg and heart rate <60 bpm; vasodilator monotherapy causes reflex tachycardia that worsens aortic shear and must be avoided
C) IV hydralazine — direct arterial vasodilation without cardiac rate effects is preferred in aortic dissection to avoid the negative inotropic effects of beta-blockers
D) IV phentolamine — alpha-1 blockade is preferred in suspected aortic pathology because sympatholytic vasodilation reduces aortic wall tension without affecting heart rate
E) IV sodium nitroprusside alone — direct arterial vasodilation is the only mechanism needed; heart rate control is not a priority in managing aortic wall stress

ANSWER: B

Rationale:

This question asked you to identify the most appropriate antihypertensive approach for suspected acute aortic dissection. Option B is correct: this presentation is strongly consistent with acute aortic dissection — sudden severe tearing chest and back pain and widened mediastinum on CXR. Aortic dissection requires a specific BP management approach: the goal is to reduce not only mean BP but also the cardiac rate of pressure rise (dP/dt) — the pulsatile shear force with each heartbeat that propagates the dissection. A rapid heart rate generates high dP/dt regardless of mean BP, so heart rate reduction is the first priority. IV beta-blockers — labetalol (combined alpha and beta blockade) or esmolol (ultra-short-acting selective beta-1 blocker) — are given first to achieve heart rate below 60 bpm, after which a vasodilator (IV nicardipine or sodium nitroprusside) is added if systolic BP remains above 120 mmHg. Vasodilator therapy without prior heart rate control causes reflex tachycardia through baroreceptor activation — worsening aortic wall shear force and propagating the dissection.

Option A: Option A is incorrect — oral agents have inadequate onset speed and titratability for this life-threatening emergency.
Option C: Option C is incorrect — hydralazine causes significant reflex tachycardia and increases dP/dt.
Option D: Option D is incorrect — phentolamine is a pure alpha-1 blocker that causes reflex tachycardia, which is specifically harmful in aortic dissection.
Option E: Option E is incorrect — sodium nitroprusside alone causes reflex tachycardia, which is contraindicated; heart rate control must precede or accompany vasodilator therapy.

BEFORE YOU MOVE ON

You have worked through 22 questions covering the full diagnostic and evaluative framework for hypertension — BP measurement errors, ABPM and HBPM thresholds, the four BP phenotypes, non-dipping significance, the baseline workup for newly diagnosed hypertension, secondary cause recognition and investigation, the pharmacological mechanisms of drug-induced hypertension from NSAIDs, oral contraceptives, calcineurin inhibitors, SNRIs, and VEGF inhibitors, the alpha-before-beta rule for pheochromocytoma, the ARR and its medication interferences, the dexamethasone suppression test, treatment initiation criteria, inter-arm BP difference evaluation, and BP management in aortic dissection. Tier 1 takes these foundations into more complex clinical territory — patients where two findings compete for diagnostic priority, workup sequences that must be correctly ordered, and scenarios where the pharmacological mechanism determines the safe clinical course.